Summary

The first U.S. clinical trial of psilocybin-assisted therapy in veterans with PTSD who got no relief from conventional treatments found that the protocol was safe, with no serious adverse events or increases in suicidal thinking or behavior. But the preliminary clinical results exceeded researchers' expectations: In the pilot trial with 12 veterans, 75% of participants were in remission one month after the study ended. Their symptoms no longer met the criteria for post-traumatic stress disorder.

AI summaries can be wrong sometimes—always verify important details using the source article.